
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
19 February 2024
Leukaemia UK launches new Patient Care Pioneer Award funding initiative
Leukaemia UK is delighted to launch a brand-new funding scheme in 2024, intended specifically for innovative, patient-focussed applied research and targeting UK-based healthcare professionals. The first of its kind for…
20 October 2023
Emerging leaders accolade for former Leukaemia UK John Goldman Fellows
Former Leukaemia UK John Goldman Fellows, Dr Matthew Blunt, University of Southampton and Dr Konstantinos Tzelepis, University of Cambridge have been recognised as ‘Emerging Leaders in Leukaemia’ by the major…
21 December 2023
‘It was the worst Christmas of my life’: Georgia Harrison reflects on ‘traumatising’ loss in charity’s Christmas Appeal
TV personality Georgia Harrison is supporting Leukaemia UK’s Christmas Appeal to help fund research into kinder, more effective treatments for leukaemia, after losing her childhood best friend to the devastating…
25 November 2025
Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl
Today, NICE announced its recommendation for Aucatzyl (obecabtagene autoleucel), a CAR-T therapy, to be made available on the NHS for treating adults aged 26 and over with relapsed or refractory…